750
Participants
Start Date
June 5, 2014
Primary Completion Date
October 14, 2016
Study Completion Date
October 14, 2016
Meningococcal group B Vaccine, rMenB+OMV NZ
4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
Meningococcal ACWY Conjugate Vaccine, MenACWY
4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
GSK Investigational Site, Morelia
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Córdoba
GSK Investigational Site, Mexico City
GSK Investigational Site, Mexico City
GSK Investigational Site, Mexico City
Lead Sponsor
GlaxoSmithKline
INDUSTRY